Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 6c, beats revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $214.00 -0.3%
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32 million versus the consensus estimate of $941.99 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
- Top restaurant stocks to watch, according to Raymond James
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
